Tendencias21

Potential new drug effective in breast cancer and melanoma resistant to targeted therapies

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

Fuente : http://www.eurekalert.org/pub_releases/2013-10/aaf…

RedacciónT21

RedacciónT21

Hacer un comentario